DRIVE2Simplify Exploratory Analysis: Metabolic Outcomes With Islatravir Plus DOR vs DOR/3TC/TDF in ART-Naive Adults at Wk 48

March 8-11, 2020; Boston, Massachusetts
Changes in weight, body fat, BMD, and fasting lipid parameters were comparable among varying doses of islatravir + DOR vs DOR/3TC/TDF at Week 48 in ART-naive patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 215 KB
Released: March 14, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Limited treatment-emergent capsid resistance occurred after 28 weeks of treatment with oral or subcutaneous lenacapavir plus FTC/TAF from ID Week 2021 reported by Clinical Care Options (CCO)

Released: October 5, 2021

Switch to DTG/3TC shows high levels of efficacy, favorable safety and tolerability, and high barrier to resistance through 3 years from IDWeek 2021 presented by Clinical Care Options (CCO)

Released: October 5, 2021

Diapositivas descargables creadas por expertos que analizan los desarrollos clínicos más importantes en el manejo del VIH desde el año pasado

Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD Daniel R. Kuritzkes, MD Darcy Wooten, MD
Released: October 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue